Biohaven Pharmaceutical Holding Co Ltd. (BHVN) saw its stock soar by 12.58% in intraday trading on Tuesday, following the company's announcement of a proposed public offering of common shares. The significant uptick in share price suggests that investors are reacting positively to this financial move by the pharmaceutical firm.

According to the company's statement, Biohaven has commenced an underwritten public offering of $150 million of its common shares. This substantial offering is likely aimed at raising capital for the company's operations, research and development, or other strategic initiatives. The market's enthusiastic response indicates that investors view this capital raise as a promising step for Biohaven's future growth and financial stability.

While public offerings can sometimes lead to stock dilution and negative price movements, the strong positive reaction in Biohaven's case suggests that the market sees potential value in how the company plans to use the raised funds. Investors will be keenly watching for further details on how Biohaven intends to allocate this new capital and what it might mean for the company's pipeline and overall strategy in the pharmaceutical sector.